Advanced Biomed Inc. (ADVB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.4 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ADVB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.52) and Max Pain ($2.77) forces dealer call-delta covering toward $25.44.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Advanced Biomed Inc. (ADVB) dropped -11.41% to $2.64, trading at 2% of its 52-week range ($2.25 – $24.23). Stretched risk/reward at current multiples (-9% return on capital) under elevated 10-year interest-rate pressure.
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC) shares rose
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ADVB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ADVB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Advanced Biomed Inc. (ADVB) ranks #904 by composite RQD confidence (32/100, grade E) and #955 by equity capitalization ($4.4M). Within this direct 5-issuer industry benchmark cohort, ADVB leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ADVB at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADVB
ACTIVE
Advanced Biomed Inc. | E | 32/100 | — | — | -9.1% | -11.41% | $4.4M | Benchmark Subject |
| ACON Aclarion Inc. | E | 24/100 | — | 9.0% | -35.0% | -3.43% | $5.7M | /acon-vs-advb → |
| BGLC BioNexus Gene Lab Corp | E | 30/100 | — | 14.6% | -35.0% | -7.79% | $2.9M | /bglc-vs-advb → |
| AMS American Shared Hospital Services | E | 29/100 | — | 18.0% | -13.8% | -5.26% | $8.4M | /ams-vs-advb → |
| SERA Sera Prognostics Inc. (Class A) | D- | 40/100 | — | -30.0% | -35.0% | +1.48% | $81.3M | /sera-vs-advb → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Advanced Biomed Inc. (ADVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.3M, operating cash flow of -$5.8M, and free cash flow of -$5.9M (-166.2% YoY). On the balance sheet, ADVB closed FY2025 with $10.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$3.3M | -$5.8M | -$5.9M | $10.9M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$2.8M | -$2.1M | -$2.2M | $4.5M | — |
As of 2026-11-01, Advanced Biomed Inc. (NASDAQ: ADVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.64 (-11.41% 1D, market cap $4.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ADVB ranks #904 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), ADVB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -9.1%. By comparison, ACON (Aclarion Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M) and BGLC (BioNexus Gene Lab Corp) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, ADVB leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).
Per ADVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001941029), Advanced Biomed Inc. generated $0 in revenue, -$3.3M in net income, and -$5.9M in free cash flow against $10.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ADVB last traded at $2.64 (-11.41% on volume of 26,235 shares), positioning the stock -59.51% below its 50-day simple moving average ($6.52) and -55.41% below its 200-day simple moving average ($5.92). Across its 52-week range of $2.25 to $24.23, ADVB sits at the 1.8% percentile with a 14-day RSI of 20.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.31 to $2.97).
Why ADVB Stock dropped -11.41% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-9% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.